Cancer Center Support Grants (CCSGs) for NCI-Designated Cancer Centers

NOTE: This FOA has expired. It was reissued as PAR-21-321 in October 2021. Check the NIH Guide for the current version.

Research Focus & Contribution

This program supports P30 Cancer Center Support Grants to establish and sustain NCI-designated Cancer Centers as integrated research enterprises. Centers conduct discovery across basic laboratory research, clinical research, and prevention/cancer control/population-based science, with emphasis on transdisciplinary collaboration that bridges these domains. The program aims to develop more effective approaches to cancer prevention, diagnosis, and therapy while serving as regional and national resources for cancer research infrastructure. Centers establish formal Research Programs with competitive funding, develop Shared Resources (technologies, services, scientific consultation), provide developmental funding for emerging priorities, coordinate cancer clinical trials, and engage catchment-area populations in research and community outreach.

Three center types are supported: Comprehensive Cancer Centers (depth and breadth across all three scientific areas with substantial transdisciplinary research); Clinical Cancer Centers (focused on basic laboratory, clinical, and prevention/control science); and Basic Cancer Centers (primarily basic laboratory research with pre-clinical translation linkages).

At-a-Glance

• Who can apply: Institutions with NCI designation or seeking designation; must demonstrate critical mass of cancer-relevant research and meet six essential characteristics (physical space, organizational capabilities, transdisciplinary collaboration, cancer focus, institutional commitment, qualified director).
• Funding & project length: Not stated in this excerpt.
• Award mechanism: P30 Center Core Grant (multi-project format).
• Key dates: Posted November 4, 2019; earliest submission December 25, 2019; expired October 12, 2021 (reissued as PAR-21-321).
• Best fit for: Research institutions with established cancer research portfolios seeking to integrate basic, clinical, and population science through shared infrastructure and team-based discovery.